Skip to main content
. 2022 Jun 6;9:878211. doi: 10.3389/fcvm.2022.878211

Table 2.

Patients' follow-up.

Whole cohort
N = 99(%)
ICI regimens Pembrolizumab 71 (72%)
Nivolumab 7 (7%)
Atezolizumab 8 (8%)
Durvalumab 11 (11%)
Other 2 (2%)
Single agent or combined Monotherapy 33 (33%)
Combinaison 66 (67%)
Line of treatment 1st line 60 (61%)
2nd line 33 (33%)
≥3rd line 6 (6%)
Myocarditis 3 (3%)
Follow-up Median follow-up (days) 209 [147; 249]
Mortality rate 28 (28%)

ICI, Immune checkpoint inhibitors.